6 / 49
Active Immunotherapy with High-Dose IL-2 in
Patients With Melanoma or RCC
IL-2: a potentially curative therapy for melanoma or RCC in 5–10% of patients
1
Curve shows the probability of dying from cancer in patients with a complete response to high-dose IL-
2
2,a
Of 33 patients with complete response, 27 remain in complete response at 39 to >148 months
2
IL-2 is associated with severe AEs, including capillary leak syndrome, which can result in potentially
fatal hypotension and reduced organ perfusion, and impaired neutrophil function
3
RESPONSE OF PATIENTS TREATED WITH HIGH-DOSE BOLUS IL-2
Compllete
response
Partial
response
Diagnosis
Total
Number of patients (%)
Total (%)
Melanoma
182
12 (6,6)
15 (8,2)
27 (14,8)
Renal
227
21 (9,3)
22(9,7)
43 (19,0)
Total
409
33 (8,1)
37 (9,0)
70 (17,1)